Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Neurocrine Biosciences Inc (NBIX) – Neurocrine Biosciences Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Neurocrine Biosciences (NBIX) trades at $152.25, up 1.78% on the day, reflecting strong momentum after consistently beating earnings estimates. The stock exhibits a bullish technical posture with support near $148 and resistance at $152. Fundamentally, the company reported robust Q1 2026 results with revenue up 44% year-over-year to $811.0 million and EPS of $1.94 beating expectations. Recent developments include the planned acquisition of Soleno Therapeutics and positive clinical data for its pipeline, signaling growth potential.
The outlook for NBIX is positive, driven by strong execution, product growth, and strategic acquisitions. Investment opportunities include upside to the consensus price target of $184 and expansion in key therapeutic areas. Risks involve integration challenges from the Soleno deal, competitive pressures, and market volatility. The stock's current valuation multiples suggest growth expectations are priced in, requiring continued execution to justify further gains.
Read full analysis

Key Stats

  • Market Cap
    $15.31B
  • Sector
    Health
  • 3M Drawdown
    -5.34%
  • Enterprise Value
    $14.40B
  • Dividend Yield
    -
  • Typical Hold Time
    2 days
$152.72
52W Low: $115.71
09 May 2025
52W High: $155.63
10 Dec 2025

Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $15.31B, with an enterprise value of $14.40B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $115.71 and a high of $155.63, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -5.34%, reflecting recent price volatility. On average, investors hold Neurocrine Biosciences Inc for approximately 2 days, indicating typical investor behavior on the platform.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.


Technical Indicators
|
|
|
Overall Summary
Bearish (1)Neutral (9)Bullish (17)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $15.31B
  • Sector
    Health
  • 3M Drawdown
    -5.34%
  • Enterprise Value
    $14.40B
  • Dividend Yield
    -
  • Typical Hold Time
    2 days
$152.72
52W Low: $115.71
09 May 2025
52W High: $155.63
10 Dec 2025

Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $15.31B, with an enterprise value of $14.40B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $115.71 and a high of $155.63, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -5.34%, reflecting recent price volatility. On average, investors hold Neurocrine Biosciences Inc for approximately 2 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!